Welcome!

Welcome to this issue of the HEAL Data2Action (HD2A) Digest! Please share with colleagues, friends, and anyone else you know who might be interested in our work and encourage them to subscribe to our newsletter.

Medications for opioid use disorder (MOUD) are the gold-standard treatment, but less than 30% of people with opioid use disorder receive them. Financing barriers play a key role in this lack of access to MOUD, such as insurance requirements for prior authorization, and mismatches between fee-for-service financing models and MOUD care delivery structures.

The Research Adoption Support Center (RASC) and the Center for Dissemination & Implementation at Stanford (C-DIAS) recently produced a series of resources that work together to help you further your understanding of the basics of payment policy in the United States and learn about opportunities to reform and innovate. Visit our website today to download the resources!

Dr. Meredith C.B. Adams received the prestigious 2024 Rising Star Pain Research Award at the May NIH HEAL Initiative PURPOSE Meeting, hosted by The Pain Research Network. This distinguished award is designed to recognize early-career researchers who demonstrate exceptional potential and innovation in the field of pain research. Dr. Adams's innovative portfolio of pain research is in alignment with the NIH HEAL goals to enhance chronic pain care and mitigate opioid misuse and abuse, supported by a substantial $27 million in research funding. Additionally, Dr. Adams has showcased a robust track record of research contributions through her publications, presentations, and scholarly activities, further solidifying her impact on the field of pain research.

Innovation Project Update

Fatal Drug Overdose Touchpoints Dashboard

The Management Performance Hub partnered with the Indiana University Schools of Medicine and Informatics, RTI International, the Indiana Department of Health, the Department of Homeland Security, the Indiana State Police, the Professional Licensing Agency, the Department of Correction, and the Governor’s Drug Prevention, Treatment, and Enforcement (DPTE) Office, to develop a real-time public-facing dashboard displaying touchpoints that occurred prior to a fatal overdose. This collaboration was funded by the National Institutes of Health (NIH) under the HEAL Data2Action Program (HD2A) as a component of the Fatal Overdose Review Teams Research to Enhance Surveillance Systems (FORTRESS) project. The primary objective of the project is to equip County Overdose Fatality Review Teams with a dashboard on local overdose intervention points to surveil patterns in poisoning events and identify opportunities to intervene prior to a fatal drug overdose. Learn more about the full project

The dashboard below displays touchpoints, as captured through state administrative datasets, that an individual experienced prior to a fatal overdose. The touchpoints are displayed by prevalence, frequency, and recency as rates and percentages, beginning in 2015.

• This is a Very Weird Moment the History of Drug Laws Interview with Keith Humphreys via The Ezra Klein Show

• Stages and Cost of Implementation Science with Lisa Saldana via That Implementation Science Podcast with Mike Pullman

• High-Dose Buprenorphine Initiation: A Scoping Review via Journal of Addiction Medicine

Notice of Special Interest

NOT-OD-24-096: Notice of Special Interest (NOSI): Promoting Data Reuse for Health Research (nih.gov)

This Notice of Special Interest (NOSI) solicits competitive revision applications that focus on data reuse and secondary data analysis in NIH-funded data repositories and knowledgebases to advance scientific inquiry and address health research questions. NIH intends to commit $275,000 direct costs per award, which can be used for up to two years. Eligible active grants that can be revised in response to this NOSI are limited to R01, U01, and cannot be used with HD2A awards specifically.

You are receiving this email because you either subscribed to receive updates from us or someone you know thinks you'd be interested in our work. If this email was forwarded to you, please subscribe to our newsletter so you can continue getting updates.